Last reviewed · How we verify
Milk of Magnesia (magnesium hydroxide)
Magnesium hydroxide (Milk of Magnesia) is one of the oldest OTC medications, in use since 1880. Serves as both an antacid and osmotic laxative. Available generically.
At a glance
| Generic name | magnesium hydroxide |
|---|---|
| Also known as | Milk of Magnesia, Phillips\, , |
| Sponsor | Generic (multiple manufacturers) |
| Drug class | Osmotic laxative, Antacid |
| Target | Gastric acid (direct neutralization) + osmotic effect in intestine |
| Modality | Inorganic salt |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1880-01-01 (United States) |
Approved indications
- Constipation
- Gastric Hypersecretory Conditions
- Gastroesophageal reflux disease
- Heartburn
- Heartburn Prevention
- Hiatal Hernia with Reflux Esophagitis
- Incomplete passage of stool
- Indigestion
- Peptic ulcer
Common side effects
Key clinical trials
- Bayesian Pragmatic Trial for Pubertal Induction in Turner Syndrome: TRansformation Initiative For Efficient Clinical TriAl Design Advancement in RarE Diseases (TRIFECTA-DARED Framework) (Phase 2)
- A Phase I Study of Arsenic Trioxide and Ascorbic Acid (ATO/AA) in Combination With Low Dose Velcade-Thalidomide-Dexamethasone (VTD) in Relapsed/Refractory Multiple Myeloma (MM) (Phase 1)
- Effect of Antacids on the Pharmacokinetics of Raltegravir in Healthy Volunteers (Phase 1)
- A 3 Arm, 5 Phase Study to Determine the Effect of Divalent and Monovalent Metal Containing Antacids and Multivitamins on the Pharmacokinetics of Raltegravir in Healthy Volunteers (Phase 1)
- Pharmacokinetics and Metabolism of a Single Dose of [14C] BMS-986256 in Healthy Male Participants (Phase 1)
- A Randomized, Partially Blind, Placebo Controlled, Crossover, Single Oral Dose Study to Assess the Effect of Concomitant Antacid (Calcium Carbonate / Magnesium Hydroxide) on the Pharmacokinetics and P (Phase 2)
- A Phase 1, Open-Label, Single Center, Single-Dose, Randomized, 4-Way Crossover Study to Assess the Effect of an Antacid on the Bioavailability of Febuxostat After Oral Administration of a 80 mg Febuxo (Phase 1)
- Comparison of an Antacid/H2-Receptor Antagonist/Proton Pump Inhibitor Versus a Proton Pump Inhibitor/H2-Receptor Antagonist/Antacid Treatment Strategy for Patients With New Onset Dyspepsia in General (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Milk of Magnesia CI brief — competitive landscape report
- Milk of Magnesia updates RSS · CI watch RSS
- Generic (multiple manufacturers) portfolio CI